Sevikar HCT - treatment opportunity for patients with essential hypertension - SeviTarget

Trial Profile

Sevikar HCT - treatment opportunity for patients with essential hypertension - SeviTarget

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Sep 2016

At a glance

  • Drugs Olmesartan medoxomil/amlodipine/hydrochlorothiazide (Primary)
  • Indications Essential hypertension
  • Focus Adverse reactions
  • Acronyms SeviTarget
  • Sponsors Daiichi Sankyo Europe
  • Most Recent Events

    • 03 Apr 2014 Status changed from active, no longer recruiting to completed as reported by German Clinical Trials Register.
    • 11 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by German Clinical Trials Register.
    • 21 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top